All data are based on the daily closing price as of July 12, 2024
d

Daewon Pharmaceutical

003220.KO
11.15 USD
-0.16
-1.41%

Overview

Last close
11.15 usd
Market cap
236.32M usd
52 week high
13.87 usd
52 week low
10.06 usd
Target price
15.77 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
0.5712
Price/Book Value
1.1307
Enterprise Value
321.70M usd
EV/Revenue
0.7914
EV/EBITDA
8.6866

Key financials

Revenue TTM
408.51M usd
Gross Profit TTM
127.07M usd
EBITDA TTM
41.02M usd
Earnings per Share
N/A usd
Dividend
0.22 usd
Total assets
416.68M usd
Net debt
N/A usd

About

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
  • Symbol
    003220.KO
  • Exchange
    KO
  • Isin
    KR7003220001
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
  • Headquarter
    Seoul
  • Web site
    https://www.daewonpharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top